← Back to Patent Explorer
US3987085A Expired / Lapsed US ⏱️ 0.0 years remaining

8β,11β,12α-PGF2.sub.α compounds

Assignee: Pharmacia and Upjohn Co
•
Filing: 1974-10-29
•
Granted: 1976-10-19
•
Expires: 1994-10-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention is a group of 8-β, 12-α-PG 2 (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.

Inventors

  • 👤 Ernest W. Yankee

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 12:12
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/93; C07D307/935; C07C; C07C405/00; C07D303/00; C07D303/02; C07D303/38; C07D303/40; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/0834; C07F7/18; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/40; C07F9/4003; C07F9/4006; C07F9/4018; C07F9/4056; C07F9/4059; C07F9/54; C07F9/5407

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 107 words
An optically active compound of the formula ##EQU1## wherein R 4 , R 5 , and R 7 are hydrogen or methyl, being the same or different; with the proviso that at least one of R 4 and R 5 is methyl; and wherein R 13 is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically, acceptable salts thereof wherein R 13 is hydrogen.
Claim 2
Dependent Claim 107 words
An optically active compound of the formula ##EQU1## wherein R 4 , R 5 , and R 7 are hydrogen or methyl, being the same or different; with the proviso that at least one of R 4 and R 5 is methyl; and wherein R 13 is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically, acceptable salts thereof wherein R 13 is hydrogen.
Claim 3
Dependent Claim 14 words
A compound according to claim 1, wherein R 4 and R 5 are methyl.
Claim 4
Dependent Claim 9 words
16,16-Dimethyl-8β,11β,12α-PGF 2 .sub.α, a compound according to claim 2.
Claim 5
Dependent Claim 11 words
16,16-Dimethyl-8β,11β,12α-PGF 2 .sub.α, methyl ester a compound according to claim 2.
Claim 6
Dependent Claim 100 words
An optically active compound of the formula ##EQU2## wherein R 13 is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R 13 is hydrogen; wherein R 22 is alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R 13 is hydrogen.
Claim 7
Dependent Claim 100 words
An optically active compound of the formula ##EQU2## wherein R 13 is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R 13 is hydrogen; wherein R 22 is alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R 13 is hydrogen.

References Cited (Backward Citations)

US3812179A Cited
FR2119855A1 Cited
US3862984A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-10-19 1980-04-19 1980-10-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-10-19 1984-04-19 1984-10-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-10-19 1988-04-19 1988-10-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag